Asciminib monotherapy as frontline treatment of chronic phase chronic myeloid leukemia: results from the ASCEND study

David T. Yeung, Naranie Shanmuganathan, John Reynolds, Susan Branford, Mannu Walia, Agnes S.M. Yong, Jake Shortt, Lynette Chee, Nicholas Viiala, Ilona Cunningham, David M. Ross, Alwyn D'Souza, Matthew Wright, Rosemary Harrup, Cecily Forsyth, Robin Filshie, Steven Lane, Peter Browett, Carolyn Grove, Andrew P. GriggTimothy P. Hughes

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for patients with chronic phase chronic myeloid leukemia (CP-CML) failing ≥2 prior lines of therapy. The Australasian Leukaemia and Lymphoma Group conducted the Asciminib Evaluation in Newly Diagnosed CML study to assess efficacy of asciminib for newly diagnosed CP-CML. Patients commenced asciminib 40 mg twice daily. Patients with treatment failure, defined as BCR::ABL1 of >10% at 3 or 6 months, or >1% at 12 or 18 months, received either imatinib, nilotinib, or dasatinib in addition to asciminib. In patients with suboptimal response, defined as levels of 1% to 10% at 6 months, >0.1% to 1% at 12 months, or >0.01% to 1% at 18 months, the asciminib dose was increased to 80 mg twice daily. With a median follow-up of 21 months (range, 0-36), 82 of 101 patients continue asciminib. Most common reasons for treatment discontinuation were adverse events (6%), loss of response (4%), and withdrawn consent (5%). There were no deaths; 1 patient developed lymphoid blast crisis. The coprimary end points were early molecular response (BCR::ABL1 of ≤10% at 3 months), achieved in 93% (96% confidence interval [CI], 86-97%), and major molecular response by 12 months achieved in 79%; (95% CI, 70-87%), respectively. Cumulative incidence of molecular response 4.5 was 53% by 24 months. One patient had 2 cerebrovascular events; no other arterial occlusive events were reported. Asciminib as frontline CP-CML therapy leads to high rates of molecular response with excellent tolerance and a low rate of discontinuation for toxicity. This trial was registered at https://www.anzctr.org.au/ as #ACTRN12620000851965.

Original languageEnglish
Pages (from-to)1993-2001
Number of pages9
JournalBlood
Volume144
Issue number19
Early online date5 Aug 2024
DOIs
Publication statusPublished - 7 Nov 2024

Fingerprint

Dive into the research topics of 'Asciminib monotherapy as frontline treatment of chronic phase chronic myeloid leukemia: results from the ASCEND study'. Together they form a unique fingerprint.

Cite this